Context. Estimation of six-month prognosis is essential in hospice referral decisions, but accurate, evidence-based tools to assist in this task are lacking.
Introduction
Prognostic estimates are important in numerous medical decisions, but perhaps nowhere do they play a more critical role than in the decision to initiate hospice care. This single decision formalizes the beginning of the end-of-life period and the transition from curative to palliative goals of care for many patients, and thus implicitly embodies some estimate of prognosis. In the U.S., the decision to initiate hospice care explicitly depends on prognostic estimates because physicians must certify an expected survival of six months or less before patients can receive services under the Medicare Hospice Benefit. 1, 2 It follows that difficulties in accurately and prospectively estimating six-month mortality may be an important determinant of the underutilization of hospice servicesdand the proportionate overutilization of aggressive curative interventionsdknown to characterize end-oflife care in the U.S.
3e15 Physicians' prognostic estimates are known to be generally inaccurate and optimistically biased. 14, 16, 17 The extent and systematic nature of this inaccuracy and its correspondence with existing patterns of end-of-life care suggest that prognostic uncertaintydparticularly with respect to six-month mortalitydmay be a key determinant of hospice underutilization.
Yet, few accurate and evidence-based prognostic tools exist to help clinicians estimate six-month mortality. Consensus guidelines were developed in 1996 by the National Hospice Organization (NHO) and adopted widely by clinicians and health policymakers. 18 However, these guidelines were not evidence based and have been shown to perform poorly in predicting six-month mortality. 19, 20 Empirically derived prognostic models also have shown limited accuracy. Perhaps the best-known, most rigorously evaluated model, from the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT), used disease characteristics and physiologic variables to predict six-month mortality in critically ill patients surviving hospitalization for any of nine serious illnesses. 21 However, in a subsequent validation effort in patients with advanced lung, heart, and liver disease and a 25% sixmonth mortality, this model also demonstrated poor performance. 19 More recent modeling efforts are promising but have been limited to specific diseases, such as cancer and dementia, 22e26 or temporal endpoints other than six months. For example, models have been developed to predict shortterm (less than six months) mortality 27,28 in terminally ill patients already referred for hospice or palliative care and long-term (one year or more) mortality in hospitalized 29 or community-dwelling elders. 30, 31 These models are thus less useful for hospice referral decisions, although they demonstrate improved predictive performance, possibly because of their inclusion of patient-reported outcomes (PROs), such as self-reported functioning and well-being or health-related quality of life (HRQOL). Accumulating evidence suggests that PROs assume greater prognostic power than other variables as the end of life approaches, presumably because the dying process represents a final common pathway characterized by a relatively small set of symptoms and functional impairments. 14,32e47 PROs also are attractive as prognostic variables because they are feasibly ascertainable directly from patients.
To our knowledge, however, there have been no previous attempts to integrate HRQOL into prognostic models for six-month mortality in general patient populations. Our objective in the present study was to develop a broadly applicable prognostic model incorporating HRQOL to predict six-month mortality, the Patient-Reported Outcome Mortality Prediction Tool (PROMPT), and to explore whether such a model could have sufficient accuracy to inform hospice referral decisions.
Methods

Data Source and Sample Population
This study used data from the Medicare Health Outcomes Survey (MHOS), an annual nationwide survey of Medicare managed care beneficiaries administered by the Centers for Medicare and Medicaid Services (CMS) since 1998 (www.hosonline.org). 48e50 The MHOS surveys a random sample of 1000 Medicare beneficiaries from each managed care plan under contract with CMS (between 250 and 320 participating plans yearly). Participants complete a baseline and a two-year follow-up survey if enrolled in the same plan. Institutionalized and disabled beneficiaries are included, but patients on Medicare solely because of endstage renal disease are excluded. The MHOS uses a self-report questionnaire to collect data on patient sociodemographic characteristics, comorbidities, clinical symptoms, and HRQOL, as measured by activities of daily living (ADLs) and the Medical Outcomes Study Short Form-36 Health Survey (SF-36 Ò , version 1). 51 The MHOS is administered by mail, with telephone follow-up and administration to initial nonresponders. We used data from four MHOS cohorts: 1998e2000, 1999e2001, 2000e2002, and 2001e2003. During this time, baseline and follow-up surveys were distributed to a total of 986,530 patients, of whom 912,703 were eligible for participation (more than 65 years old, managed care enrollees, not deceased). There were 634,892 total respondents (response rate 70%); we analyzed the last survey completed by any respondent (Fig. 1) . We further limited the sample to patients for whom use of a prognostic tool for hospice decision making would be most clinically appropriate and useful, using the SF-36 health transition item to select patients reporting significantly declining health: ''Compared to one year ago, how would you rate your health in general now?'' This item is not scored in any SF-36 scale, and its use as an inclusion criterion has conceptual validity because physicians should be more apt to consider hospice referrals for patients with substantially declining health. We included only respondents who reported that their health was ''much worse'' (n ¼ 21,870); there were 3295 deaths in this group, yielding a substantially higher observed six-month mortality than in the overall MHOS sample (15% vs. 2%).
Measures
Sociodemographic characteristics included in our analysis were self-reported age, sex, race/ MHOS study sample consisting of four 2-year cohorts (1998) (1999) (2000) (2001) ethnicity, education, and current marital status.
Comorbidities included several self-reported diseases: hypertension, coronary artery disease, congestive heart failure, other heart conditions, stroke, chronic obstructive pulmonary disease (COPD), diabetes, and cancer. Arthritis, inflammatory bowel disease, and sciatica were ascertained but excluded from analyses because they are not leading causes of mortality in U.S. adults aged 65 years and older. 52 Smoking status (current, former, and never) also was ascertained.
HRQOL was measured in two ways. Functional status was assessed using six ADLs: bathing, dressing, eating, getting in or out of chairs, walking, and using the toilet. These items had three response options: ''No, I do not have difficulty''/''Yes, I have difficulty''/''I am unable to do this activity.'' We created a summary measure of the total number of ADLs for which respondents indicated ''unable to do this activity;'' scores ranged from zero to six, with higher scores indicating greater functional impairment. HRQOL also was ascertained using the SF-36 version 1, 51 a widely used, comprehensive, generic health status instrument comprising eight scales: physical functioning (10 items), role limitations because of physical health problems (four items), bodily pain (two items), general health perceptions (five items), energy/fatigue (four items), social functioning (two items), role limitations because of emotional problems (three items), and emotional well-being (five items). Response options ranged from two to six ordinal categories. SF-36 scale scores were normalized to the general U.S. population on a T-score metric (mean ¼ 50, standard deviation [SD] ¼ 10), with higher scores indicating better HRQOL.
The outcome variable was survival at six months since the last completed survey for each respondent. Vital status and date of death were obtained from the CMS Medicare Enrollment Database. Survey completion by proxy also was ascertained.
Model Development
The large number of predictor variables resulted in a substantial proportion of subjects with missing data (n ¼ 6154, representing 28% of the sample). The proxy survey completion variable had a disproportionately high frequency of missing data (11%), and to avoid dropping cases, we created a dummy variable for nonresponse to this item. Missing data for all other individual variables were less than 8% and handled through multiple imputation using the PROC MI and PROC MI-ANALYZE functions of SAS software, version 9.1.3 (SAS Institute, Inc., Cary, NC). Missing data were imputed using a Markov chain Monte Carlo method with multiple chains, creating 10 imputed ''complete'' data sets.
Because of the large number of potential predictors, especially those related to HRQOL, we made several decisions to facilitate variable selection. We incorporated SF-36 scales rather than individual items to maximize measurement precision and because scale scores are normed to the U.S. general population. To further reduce variables in the model and because an a priori theoretical justification for variable selection is lacking, we applied a backward elimination strategy with an Akaike's information criterion stopping rule 53 to a model, including all predictor variables in each imputed data set. This is equivalent to using a P-value of 0.157 for a variable with one degree of freedom. 54 We then applied the majority method, including variables selected in five or more of the 10 imputed sets. 55 Age, sex, race/ethnicity, education, proxy status, hypertension, congestive heart failure, stroke, COPD, presence of any cancer, smoking status, ADL score, and SF-36 scores for bodily pain, general health perceptions, emotional well-being, social functioning, and energy/fatigue were selected into a final model. Of the continuous variables, age showed a nonlinear association with six-month mortality and was, therefore, modeled as a restricted cubic spline with the 5%, 35%, 65%, and 95% percentiles of age.
Some variables showed counterintuitive associations with lower six-month mortality in both univariate and multivariate analyses: non-white race, low education, hypertension, stroke, greater bodily pain, and low emotional wellbeing. Some of these counterintuitive associations have been found in other studies 43,56e59 and may reflect confounding by unmeasured variables (e.g., health care access and quality), selection biases that could have altered the relative influence of competing mortality risks (e.g., restriction to a managed care sample, selection according to self-reported declining health), or the effects of illness adaptation on participants' HRQOL ratings. 60, 61 Counterintuitive associations potentially diminish the ''sensibility'' or face validity of risk prediction models for clinicians, and many modelers thus recommend excluding the variables involved. 62e64 Other modelers have additionally excluded race/ethnicity and education both because of confounding of their prognostic significance and to ethical concerns about the potential for models incorporating these variables to contribute to health disparities. 31, 65 For these reasons and to maximize parsimony, we conducted sensitivity analyses both including and excluding counterintuitively associated variables in multivariate regression models. Model fit, discrimination, and calibration were similar and, therefore, we excluded these variables. Regression coefficients and standard errors for variables in the final model were computed by averaging across the 10 imputed data sets, following Rubin's method. 66 
Statistical Analyses and Model Evaluation
Because the MHOS sample is composed of Medicare managed care beneficiaries whose access to care, health status, and thus mortality might differ from the general U.S. population, 67 we generated life tables 68, 69 comparing overall survival of the MHOS sample with that of the year 2000 general U.S. population to assess representativeness. We also calculated descriptive statistics on sociodemographic and health-related characteristics of the sample.
We used k-fold cross-validation (k ¼ 10) to validate the model. Each of the 10 imputed data sets was randomly partitioned into k subsamples, with each subsample used once as the validation set and the remaining k À 1 set used as the training set. We assessed model discrimination by calculating the c-statistic or area under the receiver operating characteristic curve, averaging the c-statistics across all imputed data sets and cross-validation samples. 70 To further evaluate prognostic performance of the final model, we computed estimated sixmonth mortalities of individuals within each of the 10 imputed data sets and obtained mortality estimates by averaging across them. We assessed calibration by dividing patients into seven overlapping groups according to their predicted six-month mortality risk ($0.1, $0.2,., $0.7) and comparing the average predicted six-month mortality in each group with the actual proportion of patients who died in six months. To assess calibration graphically across estimated risk strata, we used a nonparametric method (PROC LOESS; SAS Institute, Inc., Cary, NC) to produce a smoothed high-resolution calibration curve with histogram plot. 71 We then calculated sensitivity, specificity, positive and negative predictive values (PPVs and NPVs), and positive and negative likelihood ratios (LRsþ and LRsÀ) at different estimated mortality risk thresholds to compare performance characteristics of the PROMPT with those of the NHO guidelines and SUPPORT model, reported by Fox et al. 19 Finally, we generated Kaplan-Meier curves to compare extended survival of respondents across all risk strata.
Results
The MHOS and general U.S. population survival curves were similar (Fig. 2) , although the MHOS sample had slightly better survival than the U.S. population; the ages at median survival probability were 85 and 83 years, respectively, for the MHOS and U.S. populations. Table 1 shows the distribution of sociodemographic characteristics, comorbidities, and HRQOL. Table 2 shows the 11 variables included in the PROMPT and their associations with six-month mortality in the entire study sample. HRQOL variables included ADLs, general health perceptions, social functioning, and energy/fatigue. The c-statistic obtained from 10-fold cross-validation was 0.752, indicating good overall discrimination. The model was well calibrated at lower estimated risk values; however, for estimated risk greater than 50%, it overestimated mortality, likely reflecting the small number of events at higher risk strata (Fig. 3) . Table 3 shows the performance characteristics of the PROMPT compared with the NHO guidelines and the SUPPORT prognostic model. At estimated six-month mortality risk thresholds of 10%e70%, model sensitivity and e94.5%. LRsþ exceeded 5.0 at all risk thresholds of 40% or more, whereas LRsÀ were near 1.0. At comparable estimated risk thresholds, diagnostic performance was superior to the NHO and SUPPORT models. Fig. 4 shows Kaplan-Meier survival curves for respondents in different estimated risk strata. Observed six-month mortality corresponded well to estimated risk, supporting the model's calibration, and by 12 months more than 50% of all patients in estimated risk strata of 30% or more had died.
Discussion
In this study, we developed a new prognostic model, the PROMPT, to predict six-month mortality in community-dwelling elderly patients with self-reported declining health. The model was developed using a large diverse sample and used 11 total variables, including HRQOL, ascertained by patient self-report. The model demonstrated good calibration and discrimination overall. Importantly, diagnostic performance at various thresholds of estimated risk was superior to existing nondisease-specific models. Specificity was high and at strata of estimated six-month mortality risk of 40% or more, the model yielded LRsþ of moderate to large magnitude (5.0 or more) with respect to clinical predictiond exceeding the performance of previous models and increasing the post-test odds of death to an extent generally considered useful in clinical decision making. The model's PPV in our study population also was high and commensurate to estimated risk; 53% of patients in the 50% risk stratum died by six months, and the proportions of observed deaths were correspondingly greater in higher risk strata. On extended observation, over half of all patients with estimated six-month mortality risk of 30% or more died by 12 months. These promising performance characteristics are particularly noteworthy given the types of variables used in our model and the nature of our study population. Unlike prior prognostic efforts, the PROMPT included no physiologic or laboratory data and relatively little clinical data regarding disease characteristics or health services utilization. The study population was clinically heterogeneous, ambulatory, community dwelling, and relatively healthy, with a lower pretest mortality risk, compared with populations included in other prognostic modeling efforts and for whom hospice care is typically considered by clinicians. Yet, in spite of these significant constraints on prognostic power, the PROMPT still demonstrated superior performance compared with existing tools, such as the SUPPORT model and NHO guidelines. This supports the model's robustness and potential transportability to more narrowly defined populations with higher pretest probabilities of mortality in which prognostic performance would likely be more optimal. These conclusions remain preliminary, however, because our model has yet to be externally validated and directly compared with other tools.
The primary limitation of the PROMPT is one shared by all existing prognostic tools for predicting short-term mortality: insufficient sensitivity to ''rule out'' death in a substantial proportion of patients. This is not surprising given that there are undoubtedly numerous causal factors and trajectories in the dying process, 72, 73 and no prognostic model has accounted for them all. For the PROMPT, furthermore, comorbidities were ascertained by self-report only and some important ones, for example, dementia and renal and liver disease, were not assessed. A substantial proportion of surveys (38%) also were completed by proxy, presumably because patients were too ill or impaired to do so themselves. Finally, our selection of patients on the basis of self-reported decline in health likely also led to the inclusion of patients with acute, self-limited conditions with little impact on mortality. All these Final prognostic model based on parameter estimates calculated using entire data sample (n ¼ 21,870); pretest likelihood of six-month mortality: MHOS sample population ¼ 15%, NHO and SUPPORT evaluation population ¼ 25%. b Brd, Int, and Nar: broad, intermediate, and narrow inclusion criteria for selecting patients for hospice care eligibility, based on NHO guidelines and as operationalized by Fox et al. 19 Broad criteria required $1, intermediate required $3, and narrow required $5 of a possible seven clinical criteria specified in NHO guidelines and correspond to low, medium, and high thresholds for hospice eligibility decisions. c Risk categories for the SUPPORT model, 19 originally expressed in terms of probability of survival (#50%, #10%), now expressed in terms of probability of mortality. Fig. 4 . Kaplan-Meier survival curves for MHOS respondents in different model-estimated six-month mortality risk strata. factors likely limit the PROMPT's sensitivity and use as an exclusive means of determining hospice eligibility because this would result in the denial of hospice services for most dying patients. This limitation has led other modelers to conclude that the goal of determining individuals' risk of six-month mortality is unrealistic.
19,25
Yet, we believe that our modeling effort offers important insights for future research and that the PROMPT has significant potential utility for clinical care. Our study adds to mounting evidence of the prognostic power of HRQOL. The PROMPT's superior overall performance compared with efforts incorporating disease and physiologic variables alone supports the hypothesis that as death approaches, HRQOL assumes greater prognostic significance.
32,33 The prominent role of similar HRQOL variables in other prognostic models in elderly patients with advanced illness 24,74 further bears this out, supporting the PROMPT's validity and the value of integrating HRQOL in future modeling efforts.
Furthermore, despite its low sensitivity in ruling out imminent death, the PROMPT has significant potential to improve end-of-life care given the prevailing underutilization of hospice services, overutilization of life-prolonging interventions, and lack of more accurate, evidencebased, and explicit prognostic methods. These circumstances alone raise the possibility that use of the model could increase hospice utilization and advance care planning. Yet, the PROMPT's greatest potential value lies in its ability to confirm a poor six-month prognosis. Its very high specificity across a range of estimated mortality risks (97% or higher for all estimated risk cut points of 40% or greater) makes the PROMPT an extremely valuable tool for ''ruling in'' imminent death, with very few false positives. From both an ethical and a clinical standpoint, this function has at least as much clinical importance as ruling out death. The potential harm of a false negative estimate of six-month mortality is overly aggressive care at the end of life. Although undesirable, this outcome is arguably more tolerable than the potential irreversible harm of a false positive estimate: mistakenly labeling patients as ''dying'' and forgoing potentially beneficial or curative interventions. This ethical concern may be an important reason for physicians' clinical reluctance to render prognoses, 22, 75 and patients' reluctance to accept them. 76 The PROMPT's ability to identify imminently dying patients with very few false positives addresses this concern, providing physicians and patients with the necessary reassurance to make critical decisions about end-oflife care.
A final limitation of the PROMPT's performance is its weaker calibration at higher estimated risk levels, at which it overestimated mortality. This is likely a consequence of the small number of total deaths in these subgroups, reflecting the low overall mortality rate of the study sample (15%). In sicker populations with a higher pretest likelihood of mortality, it is possible that the model's calibration would be improved.
However, this remains to be seen, and further evaluation is needed before the PROMPT can be implemented clinically. Although the large size and geographic and clinical heterogeneity of the study population enhances the model's generalizability, it needs to be validated prospectively in other populations with differing comorbidities and experiences with health care. The target population of any predictive model determines both its clinical appropriateness and performance characteristics, including sensitivity and specificity, 77 and ours consisted of community-dwelling elders with self-reported declining health. However, the PROMPT might be more accurate and useful in alternative populations, for example, patients identified on the basis of comorbidities and health care utilization (as in the SUPPORT study 19, 21 and more recent prognostic model efforts in nursing home patients with dementia 24 ) or physicians' own prognostic estimates, 78, 79 recently operationalized through what has been termed the ''surprise question:'' 80e82 ''Would I be surprised if this patient died in the next 12 months?'' Applying our tool in such selected populationsdwith higher pretest probabilities of six-month mortalityd would likely improve prognostic performance. Future research also might fruitfully examine whether testing strategies combining multiple prognostic tools and factors could further enhance prognostic power. For example, sensitivity might be increased by using the PROMPT in parallel with other approaches, such as physicians' prognostic estimates or the CMS Local Coverage Determination guidelines 83 used by hospice providers to determine hospice eligibility.
Finally, more work is needed not only to evaluate and improve the PROMPT but to understand the optimal means and outcomes of applying prognostic models clinically. The landmark SUPPORT study demonstrated that simply providing physicians with prognostic information may not alter end-of-life decision making or patterns of care. 84 Various factors, including physician and patient attitudes 14, 22 and the structures and processes of health care may limit effective utilization of prognostic models. The feasibility of implementing a PRO-based model such as ours, which uses 11 variables but 28 individual data elements, remains to be determined. These and other potential barriers need to be better understood, along with the appropriate methods for communicating prognostic information in a sensitive, comprehensible manner. The current effort provides a foundation for such work and efforts to refine existing models and determine optimal strategies for their implementation.
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